A Need of Metrics in Cancer Economics: Myth or Hope

Novel therapies in oncology pose a weighty financial affliction with a relative shy increase in life expectancy. Cost effectiveness analyses were found critical to gauge the value of such therapies. However, validity of these approaches is interrogated due to several biases including for example pharmaceutical sponsorship or publication favoritism [1]. Purportedly, if the increase dollar spending on cancer care in the US improve outcomes; then maintaining fitted cost thresholds are crucial [1]. Nonetheless, criteria such as the Drummond's ones were found important to control the legitimacy of theses cost analyses